We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ImmunityBio beat Q2 earnings and revenue estimates as Anktiva delivered record net product sales.
IBRX posted its eighth straight quarter of sequential Anktiva net product revenue growth since launch.
IBRX expanded Anktiva's regulatory reach, with FDA label expansion review due by Jan. 6, 2027.
ImmunityBio (IBRX - Free Report) reported an adjusted loss of 8 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The loss improved 20% compared with the year-ago period’s loss of 10 cents.
Total revenues surged nearly 94% year over year to $51.2 million, beating the Zacks Consensus Estimate of $48.5 million.
Year to date, shares of ImmunityBio have skyrocketed 251% compared with the industry’s nearly 3% growth.
Image Source: Zacks Investment Research
IBRX's Product Revenue Hits a Record
The top-line performance reflected continued adoption of the company’s sole marketed drug, Anktiva, among U.S. urologists and strong market access. Net product revenues, which accounted for nearly all quarterly revenues, reached a record $50.7 million, rising 92% year over year and 15% sequentially.
The product performance marked ImmunityBio’s eighth consecutive quarter of sequential net product revenue growth since Anktiva’s commercial launch.
Other revenues totaled $0.6 million.
ImmunityBio Faces Higher Operating Costs
Total operating costs and expenses increased about 16% year over year to around $113 million.
Research and development expenses grew 10% to nearly $61 million. The increase reflected higher personnel-related costs, clinical trial expenses and external manufacturing and distribution costs.
Selling, general and administrative expenses climbed 22% year over year to about $52 million. The increase stemmed mainly from higher professional services, personnel-related and commercial expenses.
IBRX Advances Anktiva’s Regulatory Reach
Last month, the United Arab Emirates granted broad marketing authorization for Anktiva across BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for carcinoma in situ (CIS) and papillary disease, as well as metastatic non-small cell lung cancer (NSCLC). The authorization expanded Anktiva’s regulatory footprint.
An FDA filing is under review, seeking label expansion for Anktiva plus BCG in patients with BCG-unresponsive NMIBC with papillary disease without CIS. A final decision is expected by Jan. 6, 2027.
ImmunityBio also intends to submit another regulatory filing later this year, seeking to expand Anktiva’s label in patients with BCG-naïve NMIBC with CIS, with or without papillary disease. Multiple regulatory, clinical and data milestones are expected over the next 12 months.
Over the past 60 days, earnings per share (EPS) estimates for Harmony Biosciences have risen from $3.20 to $3.33 for 2026. Over the same period, EPS estimates have increased from $3.64 to $3.87 for 2027. HRMY shares have about 4% year to date.
Harmony Biosciences missed earnings in three of the trailing four quarters while meeting on one occasion, delivering an average negative surprise of 13.97%.
Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $3.02 from $2.97. Over the same period, EPS estimates for 2027 have risen from $4.81 to $5.31. LQDA shares have skyrocketed 156% so far this year.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake
Key Takeaways
ImmunityBio (IBRX - Free Report) reported an adjusted loss of 8 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The loss improved 20% compared with the year-ago period’s loss of 10 cents.
Total revenues surged nearly 94% year over year to $51.2 million, beating the Zacks Consensus Estimate of $48.5 million.
Year to date, shares of ImmunityBio have skyrocketed 251% compared with the industry’s nearly 3% growth.
Image Source: Zacks Investment Research
IBRX's Product Revenue Hits a Record
The top-line performance reflected continued adoption of the company’s sole marketed drug, Anktiva, among U.S. urologists and strong market access. Net product revenues, which accounted for nearly all quarterly revenues, reached a record $50.7 million, rising 92% year over year and 15% sequentially.
The product performance marked ImmunityBio’s eighth consecutive quarter of sequential net product revenue growth since Anktiva’s commercial launch.
Other revenues totaled $0.6 million.
ImmunityBio Faces Higher Operating Costs
Total operating costs and expenses increased about 16% year over year to around $113 million.
Research and development expenses grew 10% to nearly $61 million. The increase reflected higher personnel-related costs, clinical trial expenses and external manufacturing and distribution costs.
Selling, general and administrative expenses climbed 22% year over year to about $52 million. The increase stemmed mainly from higher professional services, personnel-related and commercial expenses.
IBRX Advances Anktiva’s Regulatory Reach
Last month, the United Arab Emirates granted broad marketing authorization for Anktiva across BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for carcinoma in situ (CIS) and papillary disease, as well as metastatic non-small cell lung cancer (NSCLC). The authorization expanded Anktiva’s regulatory footprint.
An FDA filing is under review, seeking label expansion for Anktiva plus BCG in patients with BCG-unresponsive NMIBC with papillary disease without CIS. A final decision is expected by Jan. 6, 2027.
ImmunityBio also intends to submit another regulatory filing later this year, seeking to expand Anktiva’s label in patients with BCG-naïve NMIBC with CIS, with or without papillary disease. Multiple regulatory, clinical and data milestones are expected over the next 12 months.
IBRX’s Zacks Rank
Iovance currently carries a Zacks Rank #3 (Hold).
ImmunityBio, Inc. Price
ImmunityBio, Inc. price | ImmunityBio, Inc. Quote
Our Key Picks Among Biotech Stocks
Some better-ranked stocks in the biotech sector are Harmony Biosciences (HRMY - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, earnings per share (EPS) estimates for Harmony Biosciences have risen from $3.20 to $3.33 for 2026. Over the same period, EPS estimates have increased from $3.64 to $3.87 for 2027. HRMY shares have about 4% year to date.
Harmony Biosciences missed earnings in three of the trailing four quarters while meeting on one occasion, delivering an average negative surprise of 13.97%.
Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $3.02 from $2.97. Over the same period, EPS estimates for 2027 have risen from $4.81 to $5.31. LQDA shares have skyrocketed 156% so far this year.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 54.40%.